Malignant Transformation of Giant Cell Tumour of Bone: A Review of Literature and the Experience of a Referral Centre

Int J Mol Sci. 2022 Sep 14;23(18):10721. doi: 10.3390/ijms231810721.

Abstract

Giant cell tumour of bone (GCTB) is a benign, locally aggressive primary bone neoplasm that represents 5% of all bone tumours. The principal treatment approach is surgery. Although generally GCTB is considered only a locally aggressive disease, it can metastasise, and lung metastases occur in 1-9% of patients. To date, only the use of denosumab has been approved as medical treatment for GCTB. Even more rarely, GCTB undergoes sarcomatous transformation into a malignant tumour (4% of all GCTB), but history of this malignant transformation is unclear and unpredictable. Considering the rarity of the event, the data in the literature are few. In this review, we summarise published data of GCTB malignant transformation and we analyse three cases of malignant transformation of GCTB, evaluating histopathology, genetics, and radiological aspects. Despite the rarity of this event, we conclude that a strict follow up is recommended to detect early malignant transformation.

Keywords: H3F3A; bone sarcoma; denosumab; diagnosis; giant cell tumour of bone; malignant transformation; radiological features.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Bone Neoplasms* / pathology
  • Cell Transformation, Neoplastic / genetics
  • Denosumab
  • Giant Cell Tumor of Bone* / diagnosis
  • Giant Cell Tumor of Bone* / genetics
  • Giant Cell Tumor of Bone* / pathology
  • Humans
  • Referral and Consultation

Substances

  • Denosumab

Grants and funding

This work was financially supported through funding from the institutional “Ricerca Corrente” granted by the Italian Ministry of Health.